Olin and Huntsman clear key antitrust hurdle in planned merger
Olin (OLN) and Huntsman (HUN) cleared a key US antitrust hurdle for their merger, with the HSR Act waiting period expiring. Shareholders approved the deal in August 2026. The combined entity, OlinHuntsman, aims to leverage enhanced scale and scope. Additional regulatory approvals are pending.
How this was made
The 30-second read
Why it matters
The clearance removes a major hurdle, likely supporting both stocks and creating a spread trade opportunity.
Market read
First report of a material M&A milestone for two mid‑cap chemical firms, with potential price impact.
What to watch
Integration risks and potential antitrust challenges beyond HSR waiting period.
Background
The article reports the expiration of the mandatory HSR waiting period for the Olin-Huntsman merger, a key regulatory step.
Ticker impact
HSR waiting period expired, clearing a key antitrust hurdle for Olin's merger with Huntsman.
moderate upside for OLN; potential narrowing of OLIN/HUN spread.
Clearing the HSR waiting period is a material step in a large chemicals merger, removing a major regulatory barrier.
HSR waiting period expired, clearing a key antitrust hurdle for Huntsman's merger with Olin.
moderate upside for HUN; potential narrowing of OLIN/HUN spread.
Clearing the HSR waiting period is a material step in a large chemicals merger, removing a major regulatory barrier.
Market effects
Consolidation in the chemicals sector may pressure peers' valuations.
U.S. chemicals market sees reduced competitive uncertainty.
Large merger could influence global supply chains for chlorine and related products.
Counterpoint
Deal could face tougher FTC scrutiny later, risking delay or breakup.
Key entities
- CompanyOlin Corporation
U.S. chemical and ammunition manufacturer.
- CompanyHuntsman Corporation
Global diversified chemicals manufacturer.
